Related Experiment Video

Updated: May 15, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Specific small molecule inhibitors of Skp2-mediated p27 degradation

Lily Wu1, Arsen V Grigoryan, Yunfeng Li

  • 1Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA.

Chemistry & Biology
|December 25, 2012
PubMed

Insights

New small molecules targeting the SCF-Skp2-Cks1 complex inhibit cancer cell proliferation by stabilizing the p27 protein. This approach offers a potential new strategy for treating cancers driven by the Skp2-p27 pathway.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Drug Discovery

Background:

  • The ubiquitin proteasome system regulates cell proliferation through protein degradation.
  • The SCF-Skp2-Cks1 E3 ligase complex targets the CDK inhibitor p27 for degradation, promoting cell cycle progression.
  • Skp2 overexpression and SCF-Skp2-Cks1 deregulation are linked to cancer progression and poor prognosis.

Purpose of the Study:

  • To identify small molecule inhibitors targeting the SCF-Skp2 E3 ligase activity.
  • To investigate the mechanism of inhibition and its effect on p27 levels and cell cycle progression.
  • To evaluate the potential of SCF-Skp2 inhibitors as a novel cancer therapeutic strategy.

Main Methods:

  • In silico screening of small molecules targeting the p27 binding interface of SCF-Skp2.
  • Biochemical assays to confirm inhibition of Skp2-mediated p27 degradation.
  • Cell-based assays to assess p27 accumulation and cell cycle effects in cancer cells.

Main Results:

  • Identification of small molecules that selectively inhibit SCF-Skp2 activity by disrupting p27 binding.
  • Compounds induced Skp2-dependent accumulation of p27 in cancer cells.
  • Inhibition led to cell-type-specific cell cycle arrest in G1 or G2/M phases.

Conclusions:

  • Targeting the SCF-Skp2-Cks1 complex with small molecule inhibitors is a viable strategy to block cancer cell proliferation.
  • Inhibiting Skp2-mediated p27 degradation can restore cell cycle control in cancer.
  • SCF-Skp2 inhibitors represent a promising new avenue for cancer therapy, particularly for cancers reliant on the Skp2-p27 axis.

More Related Videos

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...